Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Tong Ren Tang Chinese Medicine Company Limited (3613.HK)
HKD6.73
-0.02 (-0.30%)
HK HKSE Healthcare Medical - Pharmaceuticals
Address
Office Tower
Wan Chai, HK
Wan Chai, HK
CEO
Wang Chi
Website
tongrentangcm.com
IPO
2013-05-07
ISIN HK0000145638
Also trades on
Hong Kong Stock Exchange · 3613.HK (HKD)
Other OTC · BJTRF (USD)
Description
Beijing Tong Ren Tang Chinese Medicine Company Limited, encompassing its various affiliates, specializes in the production, distribution, and direct sale of traditional Chinese medicine and wellness items, catering to both corporate distributors and individual consumers. Its operations are geographically segmented across Hong Kong, Mainland China, and international markets. Additionally, the company provides traditional Chinese medical consultations and therapeutic services. The firm maintains a network of 23 retail stores throughout Hong Kong, complemented by 46 international outlets located across Asia, Oceania, North America, and Europe. All its offerings are sold under the well-recognized Tong Ren Tang brand. Established in 1669, the company's main office is situated in Wan Chai, Hong Kong.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD6.73
-0.02 (-0.30%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.35
Float Shares
237.04M
Free Float %
28.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.14% | -2.94% | -5.59% | -20.25% | -22.05% | -18.09% | -21.43% | -53.18% | -49.64% | -23.34% | +6.13% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
6.73
DCF (Unlevered)
16.69
+148.0%
DCF (Levered)
13.15
+95.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
14.83
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%-6.1% Q4'25: -20.6% (vs Q4'24)
-
EPS growth Medical - Pharmaceuticals: +20.2%-21.7% Q4'25: -42.9% (vs Q4'24)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+43.1% Q4'25: +90.0% (vs Q4'24)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+31.5% ★ Q4'25: +28.0% (vs Q4'24)
-
ROIC Medical - Pharmaceuticals: +6.1%+17.7% ★ Q4'25: +15.1% (vs Q4'24)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q4'25: +0.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.26× ★ Q4'25: 0.29× (vs Q4'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
613.96M
est: 636.30M (-3.5%)
|
761.05M
est: 812.92M (-6.4%)
|
970.48M
est: 1.02B (-4.8%)
|
1.08B
est: 1.10B (-1.4%)
|
1.27B
est: 1.24B (+1.8%)
|
1.51B
est: 1.50B (+1.1%)
|
1.43B
est: 1.51B (-5.0%)
|
1.32B
est: 1.09B (+20.8%)
|
1.56B
est: 1.50B (+3.7%)
|
1.73B
est: 1.60B (+8.4%)
|
1.52B
est: 1.38B (+10.8%)
|
1.61B
est: 1.57B (+2.6%)
|
1.51B
est: 1.76B (-13.8%)
|
1.67B
1.67B – 1.68B
-4.6% YoY
|
1.87B
1.84B – 1.89B
+11.6% YoY
|
2.02B
2.01B – 2.04B
+8.3% YoY
|
| EBITDA |
288.51M
est: 332.97M (-13.4%)
|
361.66M
est: 359.89M (+0.5%)
|
480.04M
est: 465.91M (+3.0%)
|
557.75M
est: 513.49M (+8.6%)
|
630.97M
est: 615.94M (+2.4%)
|
728.32M
est: 763.04M (-4.6%)
|
731.23M
est: 767.02M (-4.7%)
|
769.14M
est: 611.44M (+25.8%)
|
852.81M
est: 689.25M (+23.7%)
|
907.63M
est: 767.76M (+18.2%)
|
779.54M
est: 649.55M (+20.0%)
|
722.32M
est: 741.07M (-2.5%)
|
495.52M
est: 828.17M (-40.2%)
|
789.80M
787.96M – 791.64M
-4.6% YoY
|
881.39M
870.05M – 892.73M
+11.6% YoY
|
954.74M
947.22M – 962.27M
+8.3% YoY
|
| EBIT |
250.46M
est: 300.30M (-16.6%)
|
343.52M
est: 342.77M (+0.2%)
|
452.48M
est: 424.60M (+6.6%)
|
534.12M
est: 501.71M (+6.5%)
|
611.00M
est: 597.56M (+2.2%)
|
720.92M
est: 717.86M (+0.4%)
|
651.99M
est: 710.55M (-8.2%)
|
690.20M
est: 507.85M (+35.9%)
|
783.10M
est: 572.48M (+36.8%)
|
830.62M
est: 637.70M (+30.3%)
|
693.77M
est: 591.66M (+17.3%)
|
636.25M
est: 675.03M (-5.7%)
|
476.00M
est: 754.36M (-36.9%)
|
719.41M
717.73M – 721.09M
-4.6% YoY
|
802.84M
792.51M – 813.17M
+11.6% YoY
|
869.66M
862.80M – 876.51M
+8.3% YoY
|
| Net Income |
220.00M
est: 230.54M (-4.6%)
|
287.12M
est: 281.06M (+2.2%)
|
354.25M
est: 354.89M (-0.2%)
|
420.32M
est: 392.80M (+7.0%)
|
489.97M
est: 477.30M (+2.7%)
|
580.72M
est: 588.48M (-1.3%)
|
556.12M
est: 591.15M (-5.9%)
|
542.46M
est: 433.18M (+25.2%)
|
607.84M
est: 488.30M (+24.5%)
|
645.88M
est: 697.28M (-7.4%)
|
540.39M
est: 494.14M (+9.4%)
|
500.28M
est: 515.36M (-2.9%)
|
397.22M
est: 527.37M (-24.7%)
|
495.79M
492.97M – 503.18M
-6.0% YoY
|
561.60M
559.25M – 570.84M
+13.3% YoY
|
728.85M
720.81M – 735.74M
+29.8% YoY
|
| SGA |
169.58M
est: 156.25M (+8.5%)
|
201.01M
est: 216.67M (-7.2%)
|
232.01M
est: 248.45M (-6.6%)
|
271.51M
est: 257.26M (+5.5%)
|
320.81M
est: 308.33M (+4.0%)
|
381.48M
est: 385.32M (-1.0%)
|
363.92M
est: 388.33M (-6.3%)
|
311.14M
est: 283.47M (+9.8%)
|
341.68M
est: 319.54M (+6.9%)
|
341.68M
est: 355.95M (-4.0%)
|
410.29M
est: 343.96M (+19.3%)
|
492.00M
est: 392.42M (+25.4%)
|
390.41M
est: 438.54M (-11.0%)
|
418.22M
417.25M – 419.20M
-4.6% YoY
|
466.73M
460.72M – 472.73M
+11.6% YoY
|
505.57M
501.58M – 509.56M
+8.3% YoY
|
| EPS |
0.29
est: 0.28 (+5.3%)
|
0.35
est: 0.35 (-0.1%)
|
0.42
est: 0.40 (+5.6%)
|
0.50
est: 0.50 (+0.4%)
|
0.59
est: 0.55 (+7.5%)
|
0.69
est: 0.65 (+5.9%)
|
0.66
est: 0.72 (-8.3%)
|
0.65
est: 0.54 (+20.4%)
|
0.73
est: 0.72 (+1.9%)
|
0.77
est: 0.71 (+8.5%)
|
0.65
est: 0.59 (+10.1%)
|
0.60
est: 0.61 (-1.6%)
|
0.47
est: 0.63 (-25.4%)
|
0.60
0.59 – 0.60
-5.6% YoY
|
0.68
0.67 – 0.68
+13.4% YoY
|
0.87
0.86 – 0.88
+28.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
859.71M
OE per share TTM
1.03
Owner's Yield
14.82%
Maintenance CapEx ratio
63.25%
Maint CapEx / Avg PPE
27.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 58 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.14% | 91.7K | 0.59% |
| 2 | State Street SPDR S&P International Small Cap ETF GWX | 0.03% | 263.1K | 0.40% |
| 3 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.02% | 89.6K | 0.72% |
| 4 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.02% | 27.7K | 0.42% |
| 5 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.02% | 15.1K | 0.74% |
| 6 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.01% | 60.3K | 0.55% |
| 7 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.01% | 31.0K | 0.74% |
| 8 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.01% | 22.1K | 0.35% |
| 9 | Schwab International Small-Cap Equity ETF SCHC | 0.01% | 449.5K | 0.06% |
| 10 | Avantis Emerging Markets Value ETF AVES | 0.01% | 111.7K | 0.36% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
608.7K
Shares Outstanding
837.10M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wang Chi | Chief Executive Officer & Executive Director | 2M | male |
| Zheng Yue | Executive Vice Chairman | 1M | male |
| Fung Yi Tsang | Chief Financial Officer & Company Secretary | — | female |
| Han Yan | Executive Chairman | — | male |
| Shaochen Qu | General Counsel | — | female |
| Zheng Guo Shen | Deputy GM & General Counsel | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3613.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
